BioCentury
ARTICLE | Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

February 20, 2019 8:01 PM UTC

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and CD123. The Phase I trial is evaluating XmAb14045 to treat relapsed or refractory acute myelogenous leukemia (AML) and other CD123-expressing hematologic malignancies.

Xencor was off $2.36 to $33.72 on Wednesday...